Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
4 hedge funds and large institutions have $18M invested in Plus Therapeutics in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
223% more capital invested
Capital invested by funds: $5.56M → $18M (+$12.4M)
0% more funds holding
Funds holding: 4 → 4 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.5M |
| 2 |
Millennium Management
New York
|
-$24K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$23K |
| 4 |
AP
Atwood & Palmer
Kansas City,
Missouri
|
-$3K |
PSTV Hedge Fund Activity: Q1 2016 in Review
4 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2016, worth a combined $18M — up 223% from $5.56M a quarter earlier.
Fund positioning in PSTV was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Sabby Management, cutting an estimated $1.5M.
- 4 institutional investors held Plus Therapeutics (PSTV) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $18M of Plus Therapeutics stock for Q1 2016, up 223% quarter-over-quarter.
- 0 funds opened new Plus Therapeutics positions in Q1 2016 and 0 closed out.
- The largest Plus Therapeutics seller in Q1 2016 was Sabby Management, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2016.